We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
- Authors
Mondello, Patrizia; Mian, Michael
- Abstract
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years, remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Despite these findings, the current standard of care for DLBCL patients is still R-CHOP, and optimization of frontline therapy remains an important goal. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL.
- Subjects
LYMPHOMAS; GERMINAL centers; MOLECULAR genetics; NUCLEOTIDE sequencing
- Publication
Hematological Oncology, 2019, Vol 37, Issue 4, p333
- ISSN
0278-0232
- Publication type
journal article
- DOI
10.1002/hon.2613